The Androgen Axis in Recurrent Prostate Cancer
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Purpose. Prostate cancer that recurs during androgen deprivation therapy is referred to as androgen-independent. High levels of expression of androgen receptor and androgen receptor-regulated genes in recurrent prostate cancer suggest a role for androgen receptor and its ligands in prostate cancer recurrence. Experimental Design. Recurrent prostate cancer specimens from 22 men whose prostate cancer recurred locally during androgen deprivation therapy and benign prostate specimens from 48 men who had received no prior treatment were studied. Androgen receptor expression was measured using monoclonal antibody and automated digital video image analysis. Tissue androgens were measured using radioimmunoassay. Results. Epithelial nuclei androgen receptor immunostaining in recurrent prostate cancer (mean optical density, 0.284 ± SD 0.115 and percentage positive nuclei, 83.7 ± 11.6) was similar to benign prostate (mean optical density, 0.315 ± 0.044 and percentage positive nuclei, 77.3 ± 13.0). Tissue levels of testosterone were similar in recurrent prostate cancer (2.78 ± 2.34 pmol/g tissue) and benign prostate (3.26 ± 2.66 pmol/g tissue). Tissue levels of dihydrotestosterone, dehydroepiandrosterone, and androstenedione were lower (Wilcoxon, P = 0.0000068, 0.00093, and 0.0089, respectively) in recurrent prostate cancer than in benign prostate, and mean dihydrotestosterone levels, although reduced, remained 1.45 nm. Androgen receptor activation in recurrent prostate cancer was suggested by the androgen-regulated gene product, prostate-specific antigen, at 8.80 ± 10.80 nmol/g tissue. Conclusions. Testosterone and dihydrotestosterone occur in recurrent prostate cancer tissue at levels sufficient to activate androgen receptor. Novel therapies for recurrent prostate cancer should target androgen receptor directly and prevent the formation of androgens within prostate cancer tissue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [36]
Citations
Cites
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275 · cited 1×
“In the United States in 2003, an estimated 220,900 new cases of prostate cancer were diagnosed and 28,900 men died from prostate cancer ( 1 ).”
BackgroundMeasurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361 · cited 1×
“Despite earlier detection (2), 30% of men treated with curative intent will suffer tumor recurrence.”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · cited 3×
“Androgen receptor is expressed in recurrent prostate cancer (11, 12), androgen receptor immunostaining is nuclear (11, 12, 23), and androgen receptor-regulated genes are expressed in both androgen-stimulated and recurrent prostate cancer (24–31).”
BackgroundSteroid 5α-Reductase Deficiency in Man: An Inherited Form of Male Pseudohermaphroditism
Imperato-McGinley, J., Guerrero, L., Gautier, T., & Peterson, R. E. (1974) · Science · doi:10.1126/science.186.4170.1213 · Cited by 1,258
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253 · cited 1×
“On a molecular level, mutations have been reported in androgendependent prostate cancer with a frequency ranging from 0 (13) to 44% (14) and in recurrent prostate cancer with a frequency ranging from 0 (15) to 50% (16).”
BackgroundDUNN, J. F., NISULA, B. C., & RODBARD, D. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-53-1-58 · Cited by 1,238 · cited 1×
“Adult men have circulating DHEA levels of 25 nM derived predominantly from the adrenal glands ( 42 ).”
BackgroundThe Conversion of Testosterone to 5α-Androstan-17β-ol-3-one by Rat Prostate in Vivo and in Vitro
Bruchovsky, N., & Wilson, J. D. (1968) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)93542-8 · Cited by 1,026
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980 · cited 1×
“Growth factor kinase signaling pathways may activate androgen receptor directly (56, 57) or indirectly by regulating coactivator interactions with androgen receptor (58).”
Background
Cited by
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Self-citationMontgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
“In contrast, this ratio was markedly reversed in metastatic tumors, which displayed a DHT/testosterone ratio of f0.25:1, consistent with a prior report evaluating locally recurrent, castration-resistant primary prostate tumors ( 7 ).”
BackgroundResultInfluentialFizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Metadata
- Authors
- Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- 2Pathology and Laboratory Medicine,
- 1Departments of Surgery (Division of Urology),
- 3Pediatrics (Laboratories for Reproductive Biology),
- 4Cell and Developmental Biology, and
- Venue
- Clinical Cancer Research
- Published
- 2004-01-15
- Volume
- 10
- Issue
- 2
- Pages
- 440-448
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2140855177
- Cited by
- 675
- References
- 68
- Citations by year
- 2025: 4 · 2024: 10 · 2023: 28 · 2022: 11 · 2021: 16 · 2020: 11 · 2019: 17 · 2018: 25 · 2017: 23 · 2016: 38 · 2015: 44 · 2014: 45 · 2013: 55 · 2012: 50
- FWCI
- 23.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-77739, P01CA077739)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54-HD-35041, U54HD035041)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- recurrent prostate cancer, castration-resistant prostate cancer, androgen receptor, androgen deprivation therapy, dihydrotestosterone, testosterone, androgen receptor activation, prostate-specific antigen, androgen-regulated gene expression, androgen production
- MeSH terms
- Aged, Aged, 80 and over, Androgens, Androstenedione, Antibodies, Monoclonal, Cell Nucleus, Dehydroepiandrosterone, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Male, Middle Aged, Prostate, Prostatic Neoplasms, Radioimmunoassay, Receptors, Androgen, Recurrence, Dihydrotestosterone, Prostate-Specific Antigen, Microscopy, Video
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Androgen Axis in Recurrent Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-1146-03
- The paper
- Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004). The Androgen Axis in Recurrent Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-1146-03
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.